bioMerieux SA 's investment in Genome Therapeutics Corp. may be small by pharmaceutical standards, but it signals a significant commitment for an in vitro diagnostics company [See Deal]. The French maker of infectious disease tests and the Cambridge, MA-based genomics company are collaborating on the development of tests for infectious diseases for human and industrial applications.
BioMerieux is giving $6.2 million to Genome Therapeutics in the first year of the four-year collaboration, including a $3.75 million...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?